Tag: track

Behind CISCE with Jason: Inside a hardcore automobile manufacturer and its supplier network

BEIJING, June 8, 2026 /PRNewswire/ -- This is a report from China.org.cn Video Link: China International Supply Chain Expo, or CISCE, showcases not only...

Mercuryo Claims 60th Place in Sifted 100: Southern Europe Leaderboard, Recognising the Region’s most Innovative High-Growth Startups

LONDON, June 8, 2026 /PRNewswire/ -- Global payments infrastructure platform Mercuryo has been recognised by Sifted, a startup news service backed by the Financial Times,...

DL Holdings’ Fourth “Victoria Harbour Night Talk”: The AI Wave: Global Investment & Hong Kong Opportunities

HONG KONG, June 8, 2026 /PRNewswire/ -- The Fourth "Victoria Harbour Night Talk" concluded successfully on June 5 at Cloud 39, The Henderson, Central,...

Clear Robotics Lands $1.75M to Build the World’s Largest Fleet of Zero-Emission Autonomous Ships

HONG KONG, June 8, 2026 /PRNewswire/ -- Today, Clear Robotics, a Hong Kong founded maritime technology company, announced that it closed a $1.75 million...

Toobit Adds XLM to Fixed Earn Series with Limited-Time 60% APR

GEORGE TOWN, Cayman Islands, June 08, 2026 (GLOBE NEWSWIRE) -- Toobit, the award-winning global cryptocurrency exchange, today announces the addition of Stellar (XLM) to its high-yield Fixed Earn series, offering traders an opportunity to capture 60% APR on their staked assets.

New IBM Study Finds CIOs and CTOs Face Growing AI Control Gap as Enterprise Deployment Scales

Most surveyed technology leaders are accountable for systems they don't fully controlOnly 11% of respondents say they're completely prepared for the scale of AI...

ROSEN, LEADING INVESTOR COUNSEL, Encourages Calix, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CALX

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Calix, Inc. (NYSE: CALX) between January 28, 2026 and April 21, 2026, inclusive (the “Class Period”), of the important July 27, 2026 lead plaintiff deadline.

Barclays Investor News: If You Have Suffered Losses in Barclays PLC (NYSE: BCS), You Are Encouraged to Contact The Rosen Law Firm About Your...

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Barclays PLC (NYSE: BCS) resulting from allegations that Barclays may have issued materially misleading business information to the investing public.

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Phreesia, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PHR

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Phreesia, Inc. (NYSE: PHR) between May 8, 2025 and March 30, 2026, inclusive (the “Class Period”), of the important July 13, 2026 lead plaintiff deadline.

He Predicted Gold at $5,000. Now He Says This $2 Stock Could Be Even Bigger.

A former CIA and Pentagon advisor says Trump is weeks away from unlocking the largest untapped mineral deposit in the United States

A former CIA and Pentagon advisor says Trump is weeks away from unlocking the largest untapped mineral deposit in the United States

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.^2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),²and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).⁴ Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.^5,6

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Veritone, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VERI

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Veritone, Inc. (NASDAQ: VERI) between October 14, 2025 and April 14, 2026, inclusive (the “Class Period”), of the important July 20, 2026 lead plaintiff deadline.

Éduc’alcool welcomes Yvan Gendron as Chair of its Board of Directors

Topic: Binance Commits $250,000 to Support Frontline Ebola Response in Uganda and DRC

CORRECTION — Mysti’s Adult and Family Services Begins Statewide Rental Assistance Program Under Washington’s Health-Related Social Needs Initiative

Behind CISCE with Jason: Inside a hardcore automobile manufacturer and its supplier network

Mercuryo Claims 60th Place in Sifted 100: Southern Europe Leaderboard, Recognising the Region’s most Innovative High-Growth Startups

DL Holdings’ Fourth “Victoria Harbour Night Talk”: The AI Wave: Global Investment & Hong Kong Opportunities

Clear Robotics Lands $1.75M to Build the World’s Largest Fleet of Zero-Emission Autonomous Ships

Toobit Adds XLM to Fixed Earn Series with Limited-Time 60% APR

New IBM Study Finds CIOs and CTOs Face Growing AI Control Gap as Enterprise Deployment Scales

ROSEN, LEADING INVESTOR COUNSEL, Encourages Calix, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CALX

Barclays Investor News: If You Have Suffered Losses in Barclays PLC (NYSE: BCS), You Are Encouraged to Contact The Rosen Law Firm About Your...

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Phreesia, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PHR

He Predicted Gold at $5,000. Now He Says This $2 Stock Could Be Even Bigger.

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Veritone, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VERI

Explore

Press Releases

News & Opinion

Living

Others

Follow us